Candidíase vulvovaginal recorrente: uma doença antiga com novos desafios

Vídeo informativo sobre o panorama atual e a carga da candidíase vulvovaginal recorrente, bem como as abordagens de tratamento.
PP-PFE-BRA-2321  

Referências:
Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015;122(6):785-94.
Aballéa S, Guelfucci F, Wagner J, et al. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169.
Davis JD, Harper AL. FPIN’s clinical inquiries: treatment of recurrent vulvovaginal candidiasis. Am Fam Physician. 2011;83(12):1482-4.
Ramsay S, Astill N, Shankland G, Winter A. Practical management of recurrent vulvovaginal candidiasis. 2009. TUGSH; 14(6): 20-22.
Yano J, Sobel JD, Nyirjesy P, et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019;19(1):48.
Daruwala P, Roden M, Hannah B, Truscott L. Poster 41: Characterizing Women in the U.S. with Acute and Recurrent Vulvovaginal Candidiasis and their Unmet Needs. AJOG. 2016; 215(6): S845–S846.
Lírio J, Giraldo PC, Amaral RL, et al. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. BMJ Open. 2019;9(5):e027489.